The extra doses of Pfizer might help balance out a potential reduction in anticipated vaccine dosages, depending upon what health authorities choose to do with the Johnson & & Johnson vaccine moving on.
Federal health agencies on Tuesday recommended a pause on administering the Johnson & & Johnson single-dose vaccine while they dig deeper into reports from several women in between the ages of 18 and 48 who stated they fell ill with “a severe and unusual type of embolism”– as described by the CDC– within 2 weeks of receiving the vaccine. One of the ladies died.
Nearly 7 million doses of the vaccine have been administered in the U.S.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The CDC is set to convene a meeting on Wednesday to examine the cases.
In a declaration, Johnson & & Johnson said the health and wellness of people who use its products is its top concern.
CLICK HERE TO READ MORE ON FOX BUSINESS
Even without Johnson & & Johnsons vaccine, White House officials said they remain on track to have adequate materials to vaccinate most American grownups by the summer season.
“We believe theres sufficient vaccine in the system– Moderna and Pfizer– for all Americans who wish to get vaccinated by May 31 to do so,” said Jeff Zients, the White Houses COVID-19 response coordinator.
The Associated Press added to this report.
In a Twitter post, Pfizer CEO Albert Bourla stated the business can provide 10% more dosages than previously consented to– an overall of 220 million– by the end of May. He also stated Pfizer will have the complete 300 million doses arranged for shipment in the U.S. by the end of July, 2 weeks early.
Dr. Bob Lahita goes over the likelihood of experiencing dangers from the Johnson & & Johnson vaccine, as the federal government stops its rollout.
Moderna Inc. also reacted to the Johnson & & Johnson difficulties, emphasizing the security of its vaccine.
BENEFITS OF JOHNSON & & JOHNSON VACCINE STILL OUTWEIGH THE RISKS: DR. NESHEIWAT
Pharmaceutical huge Pfizer said Tuesday that it is prepared to ramp up production of its COVID-19 vaccine after U.S. federal companies suggested a pause on administering injections of the Johnson & & Johnson variation over health risks.